<DOC>
	<DOCNO>NCT00661180</DOCNO>
	<brief_summary>The purpose study evaluate anti-cancer activity safety Bay 43-006 , patient Chronic Myelogenous Leukemia resist Gleevec treatment , one standard medication administer patient .</brief_summary>
	<brief_title>Open Label Phase II Study BAY 43-9006 Chronic Myelogenous Leukemia ( CML ) Patients Resistant Gleevec</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Have Philadelphia chromosome positive chronic myelogenous leukemia ( CML ) chronic phase , per IBMTR criterion Have document hematologic resistance Gleevec ( Imatinib ) follow prior hematologic response Gleevec administer dos least 400 mg/d least 3 month . Have WBC &gt; 20 x 109/L study entry Have ECOG performance status . Status 0 , 1 2 Have anticipate survival least 16 week . Be able comply study procedure followup examination . Signed informed consent must obtain prior study specific procedure . Exclusion Criteria : Congestive heart failure &gt; class II define New York Heart Association Functional Classification ( NYHA ) Cardiac arrhythmia require antiarrythmics ( exclude beta blocker digoxin ) Active coronary artery disease ischemia History HIV infection chronic hepatitis B C Active clinically serious infection ( &gt; grade 2 NCICTC ) Patients seizure disorder require antiepileptic drug History solid organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>